Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-Label, Dose Escalation Study of the Safety and Tolerability of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

NCT06171750 is registered in ClinicalTrials.gov with Ankyra Therapeutics, Inc as lead sponsor.

NCT NCT06171750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06171750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-Label, Dose Escalation Study of the Safety and Tolerability of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Lead sponsor
Ankyra Therapeutics, Inc
Phase
Phase 1
Overall status
Recruiting
Start date
January 19, 2024
Completion date
June 30, 2027
Enrollment
97 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, cutaneous squamous cell carcinoma, cutaneous tumor, malignant solid tumor, metastasis to soft tissue, metastatic solid tumor, non small cell lung cancer, solid tumor, subcutaneous tumor